Completed NA INTERVENTIONAL 2-arm NCT00785018

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia (VECTOR)

Sponsor: Radboud University Medical Center

Conditions Endotoxemia Inflammation Multi Organ Dysfunction Syndrome

Interventions C1-esterase inhibitor Endotoxin administration

Updated 6 times since 2017 Last updated: Apr 21, 2011 Started: Nov 30, 2008 Primary completion: Dec 31, 2008 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00785018, this NA trial focuses on Endotoxemia and Inflammation and remains completed. Sponsored by Radboud University Medical Center, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Mar 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Mar 2022 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands